Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexacima primary series and booster study in Vietnamese infants
2017-004181-10Phase 3
- Sponsor
- Sanofi
- Start
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis and 3 more, sponsored by Sanofi. Primary endpoint: Occurrence of unsolicited systemic adverse events.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2017-004181-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004181-10.